Literature DB >> 24164152

Psychosocial impact of onychomycosis: a review.

Anna Chacon1, Katlein Franca, Alexandra Fernandez, Keyvan Nouri.   

Abstract

Onychomycosis (tinea unguium) is the most common nail disorder. Nonetheless, it requires lengthy, often ineffective treatments, and recurrence is frequent. Predominantly a disease of the elderly, onychomycosis is becoming more and more common. Besides interfering with normal nail function, fungal nail infections are relatively painful, unsightly in appearance, disrupt daily activities, and have a negative psychosocial connotation. Commonly reported psychosocial factors are embarrassment, low self-esteem, and social withdrawal. Yet advances in therapy have been achieved since these reports were made, and many of these treatment options have proven to be more effective. Thus, the impact of these advances on psychosocial well-being of patients with onychomycosis is worth analyzing. The objective of this paper is to review studies that investigated the psychosocial impact of onychomycosis on a variety of patient populations. An alternative, total patient approach that dermatologists and general practitioners alike could use to incorporate patients' psychosocial well-being into the holistic management of onychomycosis will also be discussed.
© 2013 The International Society of Dermatology.

Entities:  

Mesh:

Year:  2013        PMID: 24164152     DOI: 10.1111/ijd.12122

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  12 in total

1.  Early Visible Improvements during K101-03 Treatment: An Open-Label Multicenter Clinical Investigation in Patients with Onychomycosis and/or Nail Psoriasis.

Authors:  Bianca Maria Piraccini; Michela Starace; Anders Toft
Journal:  Dermatology       Date:  2017-08-05       Impact factor: 5.366

2.  Treatment of onychomycosis with efinaconazole 10% topical solution and quality of life.

Authors:  Antonella Tosti; Bom E Elewski
Journal:  J Clin Aesthet Dermatol       Date:  2014-11

3.  Epidemiology of Onychomycosis in an Academic Nail Unit in South Greece during a Three-Year Period.

Authors:  Stamatios Gregoriou; Nikoletta Mpali; Georgia Vrioni; Eleni Hatzidimitriou; Stella-Eugenia Chryssou; Dimitrios Rigopoulos
Journal:  Skin Appendage Disord       Date:  2019-12-19

Review 4.  The Impact of Onychomycosis on Quality of Life: A Systematic Review of the Available Literature.

Authors:  Aditya K Gupta; Rachel R Mays
Journal:  Skin Appendage Disord       Date:  2018-02-13

Review 5.  Efinaconazole in the treatment of onychomycosis.

Authors:  Shari R Lipner; Richard K Scher
Journal:  Infect Drug Resist       Date:  2015-06-01       Impact factor: 4.003

Review 6.  Onychomycosis: An Updated Review.

Authors:  Alexander K C Leung; Joseph M Lam; Kin F Leong; Kam L Hon; Benjamin Barankin; Amy A M Leung; Alex H C Wong
Journal:  Recent Pat Inflamm Allergy Drug Discov       Date:  2020

7.  Translation and Cross-Cultural Adaptation of Quality of Life Scale in Patients with Onychomycosis.

Authors:  Vasco Silva-Neves; Ana Caramelo; Paulo Alves; Carla Pais-Vieira; Alexandra Palmer Minton; Ana María Rodríguez-Leboeuf; Miguel Pais-Vieira
Journal:  Int J Environ Res Public Health       Date:  2021-05-28       Impact factor: 3.390

8.  More than Nail Deep: The Effect of Efinaconazole 10% Treatment on the Quality of Life in Patients with Onychomycosis: A post hoc Study.

Authors:  Aditya K Gupta; Maanasa Venkataraman; Emma M Quinlan; Madhulika A Gupta; Naveen Anbalagan; Rachel Lyons
Journal:  Skin Appendage Disord       Date:  2021-05-19

9.  Amorolfine 5% Nail Lacquer Exhibits Potent Antifungal Activity Compared to Three Acid-Based Devices Indicated for the Treatment of Onychomycosis: An In Vitro Nail Penetration Assay.

Authors:  Mahmoud Ghannoum; Karine Sevin; Marlis Sarkany
Journal:  Dermatol Ther (Heidelb)       Date:  2016-02-01

10.  Skin Diseases in Patients with Primary Psychiatric Disorders.

Authors:  Paraskevi Mavrogiorgou; Corinna Mersmann; Gabriele Gerlach; Stephan Herpertz; Georg Juckel
Journal:  Psychiatry Investig       Date:  2020-02-25       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.